XML 25 R19.htm IDEA: XBRL DOCUMENT
v3.25.1

Restructuring and Asset Impairments | 3 Months Ended
--- | ---
Mar. 31, 2025
Restructuring and Related Activities [Abstract] |
Restructuring and Asset Impairments | 10. Restructuring and Asset Impairment s The Company has undertaken restructuring actions impacting the reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions resulting in severance and transition costs; and costs related to the consolidation of facilities resulting in asset impairment and accelerated depreciation charges. The following table presents restructuring costs by segment as included within the Company’s consolidated statements of operations (in millions):
|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Cost of revenues: |  |  |  |  |  |
BSI BioSpin |  | $ | 1.0 |  |  | $ | — |
BSI CALID |  |  | 1.2 |  |  | — |
BSI NANO |  |  | 0.4 |  |  |  | 3.7 |
Total Cost of revenues |  | $ | 2.6 |  |  | $ | 3.7 |
Other charges, net: |  |  |  |  |  |
BSI BioSpin |  | $ | 5.8 |  |  | $ | — |
BSI CALID |  |  | 1.0 |  |  | — |
BSI NANO |  |  | 0.8 |  |  |  | 3.0 |
Corporate |  | — |  |  |  | 0.5 |
Total Other charges, net |  |  | 7.6 |  |  |  | 3.5 |
Total |  | $ | 10.2 |  |  | $ | 7.2 |
The following tables set forth the changes in restructuring reserves for the periods reported (in millions):
|  | Total |  |  | Severance |  |  | Exit Costs |  |  | Provisions for Excess Inventory |
Balance at December 31, 2024 |  | $ | 7.7 |  |  | $ | 4.6 |  |  | $ | 2.6 |  |  | $ | 0.5 |
Restructuring charges |  |  | 10.2 |  |  |  | 8.2 |  |  |  | 1.0 |  |  |  | 1.0 |
Cash payments |  |  | (7.3 | ) |  |  | (4.0 | ) |  |  | (3.3 | ) |  |  | — |
Other, non-cash adjustments and foreign currency effect |  |  | (1.3 | ) |  |  | 0.2 |  |  |  | — |  |  |  | (1.5 | )
Balance at March 31, 2025 |  | $ | 9.3 |  |  | $ | 9.0 |  |  | $ | 0.3 |  |  | $ | 0.0 |
|  | Total |  |  | Severance |  |  | Exit Costs |  |  | Provisions for Excess Inventory |
Balance at December 31, 2023 |  | $ | 13.1 |  |  | $ | 9.6 |  |  | $ | 2.9 |  |  | $ | 0.6 |
Restructuring charges |  |  | 7.2 |  |  |  | 3.0 |  |  |  | 1.4 |  |  |  | 2.8 |
Cash payments |  |  | (9.1 | ) |  |  | (7.2 | ) |  |  | (1.9 | ) |  |  | — |
Other, non-cash adjustments and foreign currency effect |  |  | (2.9 | ) |  |  | (0.1 | ) |  |  | — |  |  |  | (2.8 | )
Balance at March 31, 2024 |  | $ | 8.3 |  |  | $ | 5.3 |  |  | $ | 2.4 |  |  | $ | 0.6 |
During the three months ended March 31, 2025 and 2024, in connection with the Bruker Cellular Analysis restructuring plan, the Company recorded and accrued severance and termination charges of $0.5 million and $3.9 million respectively, and made payments of $3.0 million and $7.0 million, respectively. In addition, the Company charged $2.8 million to product restructuring costs due to scrapping of expired or expiring inventories during the three months ended March 31, 2024. The Company did no t have similar charges during the three months ended March 31, 2025. Refer to Note 12, Restructurings and Asset Impairments of the Annual Report on Form 10K for the year ended December 31, 2024 for further information on this restructuring plan.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References No definition available. + Details
Name: | us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration